Treatment-resistant depression is generally defined as depression that has failed to respond to at least two adequate antidepressant trials. Affects roughly 30% of people with major depressive disorder. Psilocybin has shown consistent symptom reduction in open-label studies; controlled Phase 2/3 trials show meaningful but smaller effects.